EMCUREPharmaceuticals
Emcure Pharmaceuticals Ltd — Profit & Loss Statement
₹1595.50
+4.14%
Emcure Pharmaceuticals Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 9.14 Cr | -0.06 Cr | -6.35 Cr | -0.66 Cr | — |
| Tax Rate For Calcs | 0.27 | 0.27 | 0.25 | 0.28 | — |
| Normalized EBITDA | 1.46K Cr | 1.24K Cr | 1.20K Cr | 1.35K Cr | — |
| Total Unusual Items | 33.66 Cr | -0.21 Cr | -25.59 Cr | -2.37 Cr | — |
| Total Unusual Items Excluding Goodwill | 33.66 Cr | -0.21 Cr | -25.59 Cr | -2.37 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 681.33 Cr | 498.18 Cr | 532.02 Cr | 662.20 Cr | — |
| Reconciled Depreciation | 384.13 Cr | 312.41 Cr | 260.12 Cr | 244.85 Cr | — |
| Reconciled Cost Of Revenue | 3.32K Cr | 2.61K Cr | 2.41K Cr | 2.39K Cr | — |
| EBITDA | 1.50K Cr | 1.24K Cr | 1.17K Cr | 1.35K Cr | — |
| EBIT | 1.11K Cr | 927.92 Cr | 910.13 Cr | 1.11K Cr | — |
| Net Interest Income | -161.50 Cr | -208.01 Cr | -179.77 Cr | -151.26 Cr | — |
| Total Other Finance Cost | 30.53 Cr | 28.08 Cr | 28.69 Cr | 28.99 Cr | — |
| Interest Expense Non Operating | 140.01 Cr | 200.69 Cr | 162.91 Cr | 132.46 Cr | — |
| Interest Income Non Operating | 9.04 Cr | 20.76 Cr | 11.83 Cr | 10.20 Cr | — |
| Operating Income | 1.08K Cr | 917.32 Cr | 940.63 Cr | 1.09K Cr | — |
| Operating Expense | 3.40K Cr | 3.06K Cr | 2.58K Cr | 2.28K Cr | — |
| Other Operating Expenses | 813.88 Cr | 745.59 Cr | 607.72 Cr | 538.78 Cr | — |
| Depreciation And Amortization In Income Statement | 384.13 Cr | 312.41 Cr | 260.12 Cr | 244.85 Cr | — |
| Amortization | 99.78 Cr | 62.78 Cr | 52.32 Cr | 53.37 Cr | — |
| Depreciation Income Statement | 284.35 Cr | 249.63 Cr | 207.79 Cr | 191.49 Cr | — |
| Selling General And Administration | 837.63 Cr | 773.75 Cr | 644.82 Cr | 572.54 Cr | — |
| Selling And Marketing Expense | 592.77 Cr | 516.58 Cr | 414.52 Cr | 397.36 Cr | — |
| General And Administrative Expense | 244.86 Cr | 257.18 Cr | 230.29 Cr | 175.18 Cr | — |
| Rent And Landing Fees | 6.63 Cr | 7.14 Cr | 6.71 Cr | 5.35 Cr | — |
| Gross Profit | 4.49K Cr | 3.97K Cr | 3.52K Cr | 3.37K Cr | — |
| Cost Of Revenue | 3.32K Cr | 2.61K Cr | 2.41K Cr | 2.39K Cr | — |
| Total Revenue | 7.81K Cr | 6.58K Cr | 5.93K Cr | 5.77K Cr | — |
| Operating Revenue | 7.81K Cr | 6.58K Cr | 5.93K Cr | 5.77K Cr | — |
| Interest Expense | 140.01 Cr | 200.69 Cr | 162.91 Cr | 132.46 Cr | — |
| Interest Income | 9.04 Cr | 20.76 Cr | 11.83 Cr | 10.20 Cr | — |
| Normalized Income | 656.82 Cr | 498.33 Cr | 551.26 Cr | 663.91 Cr | — |
| Net Income From Continuing And Discontinued Operation | 681.33 Cr | 498.18 Cr | 532.02 Cr | 662.20 Cr | — |
| Total Expenses | 6.72K Cr | 5.66K Cr | 4.99K Cr | 4.68K Cr | — |
| Rent Expense Supplemental | 6.63 Cr | 7.14 Cr | 6.71 Cr | 5.35 Cr | — |
| Diluted Average Shares | 18.09 Cr | 18.07 Cr | 18.08 Cr | 18.08 Cr | — |
| Basic Average Shares | 18.09 Cr | 18.07 Cr | 18.08 Cr | 18.08 Cr | — |
| Diluted EPS | 36.43 | 27.57 | 29.43 | 36.63 | — |
| Basic EPS | 36.43 | 27.57 | 29.43 | 36.63 | — |
| Diluted NI Availto Com Stockholders | 681.33 Cr | 498.18 Cr | 532.02 Cr | 662.20 Cr | — |
| Net Income Common Stockholders | 681.33 Cr | 498.18 Cr | 532.02 Cr | 662.20 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 681.33 Cr | 498.18 Cr | 532.02 Cr | 662.20 Cr | — |
| Minority Interests | -26.14 Cr | -29.39 Cr | -29.83 Cr | -40.36 Cr | — |
| Net Income Including Noncontrolling Interests | 707.47 Cr | 527.58 Cr | 561.85 Cr | 702.56 Cr | — |
| Net Income Continuous Operations | 707.47 Cr | 527.58 Cr | 561.85 Cr | 702.56 Cr | — |
| Tax Provision | 263.88 Cr | 199.65 Cr | 185.37 Cr | 269.99 Cr | — |
| Pretax Income | 971.35 Cr | 727.23 Cr | 747.22 Cr | 972.55 Cr | — |
| Other Non Operating Income Expenses | 14.18 Cr | 13.32 Cr | 14.94 Cr | 16.50 Cr | — |
| Special Income Charges | 27.86 Cr | -2.74 Cr | -25.71 Cr | -2.37 Cr | — |
| Other Special Charges | -27.86 Cr | -7.19 Cr | 0.33 Cr | 0.41 Cr | — |
| Net Non Operating Interest Income Expense | -161.50 Cr | -208.01 Cr | -179.77 Cr | -151.26 Cr | — |
| Write Off | — | 38.55 Cr | 25.38 Cr | 1.96 Cr | 2.53 Cr |
| Restructuring And Mergern Acquisition | — | 9.93 Cr | — | — | — |
| Net Income Discontinuous Operations | — | — | 0.00 | 0.00 | -188.66 Cr |
| Impairment Of Capital Assets | — | — | 0.00 | 0.00 | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Emcure Pharmaceuticals Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.